drugset / Trial / NCT05238649
Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
Timeline
- Start
- 2021-11-10
- Primary completion
- 2022-11-30
- Completion
- 2023-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant SARS-CoV-2 Fusion Protein Vaccine | Vaccine | 10 ug | Intramuscular |
| Subject | Recombinant SARS-CoV-2 Fusion Protein Vaccine | Vaccine | 25 ug | Intramuscular |
| Comparator | SARS-Cov-2 Vaccine Inactivated | Vaccine | 0.5 ml | Intramuscular |